中国现代医学杂志2017，Vol.27Issue(3)：79-84,6.DOI:10.3969/j.issn.1005-8982.2017.03.016
激素受体阳性乳腺癌患者卵巢抑制时机的选择及对预后的影响
Efficacy of adjuvant chemotherapy plus ovarian function suppression in premenopausal women with early-stage hormone-receptor-positive breast cancer
金光华 1张竞宇 2李雅丽2
作者信息
- 1. 中一东北国际医院乳腺外科,辽宁沈阳110623
- 2. 中国医科大学附属第四医院第五普通外科,辽宁沈阳110032
- 折叠
摘要
Abstract
Objective To assess the efficacy of chemotherapy plus ovarian function suppression therapy (Goserelin) for premenopausal women with hormone-receptor-positive and lymph-node-positive (N1) breast cancer.Methods The data of 167 premenopausal women treated in our hospital from January 2001 to October 2009 for hormone-receptor-positive and lymph-node-positive (1-3) breast cancer were retrospectively reviewed.On the basis of the use of ovarian function suppression (Goserelin) or not,the patients were categorised into two groups.In group A,55 HR-positive patients received 6 courses of chemotherapy plus 6-month ovarian function suppression followed by 5-year endocrine therapy.In group B,112 HR-positive patients only received 6 courses of chemotherapy with 5-year endocrine therapy.Results The median follow-up period was 58 months by the end of 2015.In univariate analysis,chemotherapy plus 6-month ovarian function suppression therapy improved 5-year disease-free survival (DFS) and 5-year overall survival (OS).In multivariate analysis,Goserelin treatment,lymphovascular invasion (LVI) and histological grade were the independent factors influencing DFS and OS.Conclusions For the patients ≤45 years with lymph node metastasis (1-3) and HR-positive breast cancer,chemotherapy plus 6-month ovarian function suppression therapy can result in significantly improved therapeutic efficacy.LVI and histological grade are powerful independent adverse prognostic factors and should be considered in decisions about adjuvant treatment in breast cancer patients with the positive hormone receptor and lymph node metastasis.关键词
乳腺癌/辅助化疗/卵巢去势/绝经前/激素受体Key words
breast cancer/adjuvant chemotherapy/hormone receptor/ovarian function suppression/premenopause分类
医药卫生引用本文复制引用
金光华,张竞宇,李雅丽..激素受体阳性乳腺癌患者卵巢抑制时机的选择及对预后的影响[J].中国现代医学杂志,2017,27(3):79-84,6.
